CDC3 as A Potential Drug Target/Biomarker (G83643)

Target Name: CCDC3

NCBI ID: G83643

CCDC3

CDC3 as A Potential Drug Target/Biomarker

CCDC3 (Favine), a protein that is expressed in various tissues throughout the body, has been identified as a potential drug target or biomarker. The discovery of CCDC3 as a potential drug target is based on its unique structure and the involvement of a protein known as nuclear factor kappa B (NF-kappa-B), which plays a critical role in cellular signaling.

CDC3 is a 24-kDa protein that is expressed in various tissues, including the brain, heart, liver, and kidneys. It is a member of the superfamily of RNA-binding proteins, known as the PXXP/DNA-binding proteins, and is characterized by a unique N-terminal region that contains a conserved nucleotide sequence and a distinct C-terminus.

One of the most significant features of CCDC3 is its ability to interact with the protein NF-kappa-B. NF-kappa-B is a well-known transcription factor that plays a critical role in cellular signaling and is involved in various physiological processes, including inflammation, cell growth, and survival. The interaction between CCDC3 and NF-kappa-B suggests that CCDC3 may be a potential drug target or biomarker for the inhibition of NF-kappa-B signaling.

The mechanism of the interaction between CCDC3 and NF-kappa-B is based on the presence of a unique domain in CCDC3, known as the N-terminal region, which contains a conserved nucleotide sequence that is similar to the N-terminal domain of other RNA-binding proteins. This conserved domain is known as the PXXP motif and is commonly found in proteins that interact with transcription factors. The PXXP motif is thought to play a role in the formation of a protein-protein interaction complex with transcription factors, allowing for the transfer of genetic information from the transcription factor to the target protein.

In addition to its interaction with NF-kappa-B, the N-terminal region of CCDC3 is also involved in the regulation of cellular processes, including cell adhesion, migration, and the cytoskeleton. This suggests that CCDC3 may be a potential drug target or biomarker for the regulation of cellular processes that are affected by NF-kappa-B signaling.

The potential utility of CCDC3 as a drug target or biomarker is based on its unique structure and the involvement of the PXXP motif in its interaction with NF-kappa-B. Further research is needed to determine the exact mechanism of the interaction between CCDC3 and NF-kappa-B and to explore the potential clinical applications of CCDC3 as a drug target or biomarker.

In conclusion, CCDC3 is a unique protein that has been identified as a potential drug target or biomarker based on its interaction with the transcription factor NF-kappa-B. Further research is needed to determine the exact mechanism of the interaction and to explore the potential clinical applications of CCDC3.

Protein Name: Coiled-coil Domain Containing 3

Functions: Negatively regulates TNF-alpha-induced pro-inflammatory response in endothelial cells (ECs) via inhibition of TNF-alpha-induced NF-kappaB activation in ECs (PubMed:25193116). Positively regulates lipid accumulation in adipose cells (By similarity)

The "CCDC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets